Wise R, Andrews J M, Ashby J P, Thornber D
Department of Medical Microbiology, Dudley Road Hospital, Birmingham, UK.
J Antimicrob Chemother. 1990 Aug;26(2):209-13. doi: 10.1093/jac/26.2.209.
The in-vitro activity of ceftibuten against respiratory pathogenic bacteria was studied and compared with that of other oral beta-lactam agents. Ceftibuten displayed high activity against Haemophilus influenzae and Branhamella catarrhalis. There was reduced activity against Streptococcus pneumoniae (MIC90 16 mg/l). The protein binding of ceftibuten was 77% and the primary target site PBP 3. A high degree of stability to beta-lactamase hydrolysis was observed.
